Loic Verlingue

6PUBLICATIONS
87CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 07, 2026
Procedures of data merging in precision cancer medicine: the PRIME-ROSE project.

Henk Van der Pol, Tina Kringelbach, Maria Martin Agudo

|Nov 06, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.

Capucine Baldini, Loic Verlingue, Vincent Goldschmidt

|Oct 18, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.

Aaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht

|Mar 02, 2023
Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer.

Yoann Pradat, Julien Viot, Andrey A Yurchenko

|Oct 31, 2022
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.

Patricia Martin-Romano, Laura Mezquita, Antoine Hollebecque

|Jul 01, 2021
Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials.

Julie Delorme, Valentin Charvet, Muriel Wartelle

Pageof 1

Frequent Collaborators

3 joint publications

Benjamin Besse

3 joint publications

Antoine Hollebecque

3 joint publications

Antoine Italiano

2 joint publications

Christophe Massard